-
"Star drug" "Engliflozin" new indications for marketing application accepted
Time of Update: 2021-12-06
On September 30 this year, Eli Lilly issued a press release stating that it had submitted an application to CDE for the registration of new indications for adult patients with heart failure with enpagliflozin for ejection fraction preservation .
-
Hillhouse adjusted its positions substantially in the third quarter, and the first three warehouses were all biopharmaceutical companies
Time of Update: 2021-12-06
In the third quarter of this year, BeiGene is still a major position in Hillhouse's US stocks .
In the F13 documents for the third quarter, BeiGene became a major position in Hillhouse's stock holdings, holding 5,472,300 shares, corresponding to a market value of US$1.
-
Sichuan Province issued an important notice, the purchase of oral consumables with quantity or started
Time of Update: 2021-12-06
At present, the Sichuan Pharmaceutical Equipment Bidding and Purchasing Service Center has officially started the information declaration work for the maintenance of dental implants and repair abutment medical consumables.
-
FDA delays Bristol-Myers Squibb's first-in-class cardiomyopathy drug listing application
Time of Update: 2021-12-06
The Phase III clinical results, code-named EXPLORER-HCM, showed that compared with the placebo group, Mavacamten showed clinically significant improvements in symptoms, functional status and quality of life in patients with symptomatic oHCM, reaching all primary and secondary clinical endpoints .
-
Industry: In the next 5 to 10 years, the level of China's medical equipment may be equal to that of Europe
Time of Update: 2021-12-06
In addition, in the past, China's medical equipment industry lacked some reasonable and stable incentive policies for the research and development of domestic equipment.
In addition, relevant and continuous incentive policies are also needed to encourage and support domestic pharmaceutical equipment companies to in-depth research and develop original products .
-
my country's orthopedic equipment market has a bright future, and it is expected to exceed 50 billion yuan in 2023
Time of Update: 2021-12-06
At present, driven by multiple factors such as the continuous promotion of favorable policies and the continuous advancement of science and technology, the market capacity of orthopedic medical equipment in China is showing a trend of continuous expansion .
Among them, the orthopedic implant market scale was 36 billion yuan, a year-on-year increase of 16.
-
With the rapid development of the life science industry, pharmaceutical equipment and consumables usher in a large increase in demand
Time of Update: 2021-12-06
In the context of the rapid development of the life science industry, its upstream industry chain, including related equipment, consumables, raw materials and services, has also ushered in a large increase in demand .
-
The R&D investment of local pharmaceutical companies is still "in full swing", and multinational pharmaceutical companies are also "heating up"
Time of Update: 2021-12-06
" Over 80% of the A-share listed pharmaceutical companies had increased their total R&D investment in the first three quarters compared with the same period last year .
-
Sharing economy promotes the efficient development of Chinese medicine industry
Time of Update: 2021-12-05
With the gradual development of the two pilot provinces of the National Medical Community and the 567 compact county medical community construction pilot projects , To ensure the same quality and same price of regional TCM decoction pieces, and improve the TCM service capabilities of primary medical institutions .
-
Wuhan starts the "dual channel" management of negotiation drugs, 71 kinds of drugs can be used in hospital pharmacies to apply for medical insurance
Time of Update: 2021-12-05
In order to solve the problem of "difficulty in entering hospitals" for medical insurance negotiation drugs, the two ministries and commissions of the Wuhan Municipal Medical Insurance Bureau issued a notice a few days ago to clearly include designated pharmacies in the scope of the medical insurance negotiation drug supply guarantee, forming a "dual channel" with designated medical institutions.
-
BeiGene OX40 agonist approved, clinical IL-6 inhibitor is expected to be approved in the near future
Time of Update: 2021-12-05
One is its self-developed class 1 new drug OX40 agonist BGB-A445 injection, which has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (CDE) for clinical trials; the second is its introduction of IL-6 inhibitors for injection Stuximab (siltuximab), the new drug listing application review status in China has been updated to: Pending approval, which means that the drug is expected to be approved in China in the near future .
-
Pfizer's new crown oral drug Paxlovid is $529 per course of treatment
Time of Update: 2021-12-05
On October 27th, Merck and its partner Ridgeback announced that they had reached a treatment license agreement with the United Nations to give up patents in 105 low- and middle-income countries around the world to allow them to produce generic drugs .
-
Innovation is not easy. Dozens of pharmaceutical companies have suspended or terminated the development of new drugs this year
Time of Update: 2021-12-05
In addition to Merck, according to media statistics, no less than 20 pharmaceutical companies have announced the termination or suspension of research and development in the drug field this year .
-
Why do pharmaceutical companies repeat the mistakes of Internet medical treatment in digital therapy?
Time of Update: 2021-12-05
. Of course, it is precisely because online consultation and health management are corporate benefits, users are separated from doctors, and digital therapy hopes to promote patients to get one-stop solutions from doctors .
-
Tens of billions of antithrombotic drugs have fallen into the "Altar"! TOP10 rankings have changed, Yangzijiang and others will be the first to imitate
Time of Update: 2021-12-05
The 30 billion market makes waves againSales of Fondaparinux Sodium Injection in Public Medical Institutions in China (Unit: 100 million yuan)Source: Mi Nei. com, China's public medical institutions terminal competition patternA few days ago, Yangtze River Jiangsu Zilong Pharmaceutical's Fondaparinux Sodium Injection was approved as a supplementary application, and it is the fourth company that has reviewed the product .
-
API companies are accelerating production expansion, and the pharmaceutical industry in the industry chain is expected to benefit
Time of Update: 2021-12-05
. Therefore, under the background that a large number of raw material pharmaceutical companies have established sites and upgraded and expanded their production, pharmaceutical equipment companies will also usher in more demand, and their market will continue to expand accordingly .
-
Bid opening is coming soon!
Time of Update: 2021-12-05
Specifically, the alliance regions that actually participated in the reporting of drugs in this variety range include the following provinces: Guangdong, Shanxi, Jiangxi, Henan, Hunan, Guangxi, Hainan, Guizhou, Gansu, Qinghai, Ningxia, Xinjiang, Xinjiang Production and Construction Corps, the above provinces are the regions that participated in the procurement of the inter-provincial alliance this time .
-
1.7 billion injections!
Time of Update: 2021-12-05
Bortezomib is a new type of targeted anticancer drug, and its terminal sales in China's public medical institutions will exceed 1.
-
Topical analgesics over 18 billion market, plasters "rule the king", this exclusive Ted product shines
Time of Update: 2021-12-05
Among the TOP5 products of China's public medical institutions, Tide's flurbiprofen gel plaster (Zepusi® Debam®) ranked first, with the highest growth rate and the only chemical drug on the list .
-
Antu Biocarbohydrate Antigen CA15-3 Detection Kit Obtained Medical Device Registration Certificate
Time of Update: 2021-12-05
On November 23, Antu Biological released an announcement stating that the company had recently received the "Medical Device Registration Certificate" issued by the Henan Provincial Food and Drug Administration for the carbohydrate antigen CA15-3 detection kit (magnetic particle chemiluminescence method) for In vitro quantitative detection of the content of carbohydrate antigen CA15-3 in human serum .
